Cat. No. 3389

Bicalutamide C18H14F4N2O4S [90357-06-5]

Price and Availability

For Bicalutamide pricing & availability please select your country from the drop down menu:
By clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy.

Special Conditions

No more than 1 g per individual per year to be sold without prior permission from the license holder.

Alternative Names: Casodex, ICI 176,334

Chemical Name: N-[4-Cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide

Biological Activity

Orally active non-steroidal androgen receptor antagonist (IC50 = 190 nM). Displays peripheral selectivity and does not effect serum levels of LH and testosterone. Exhibits potent anticancer activity in vivo.

Licensing Information

Sold for research purposes only under agreement from AstraZeneca

Technical Data

Soluble to 100 mM in DMSO and to 10 mM in ethanol
>99 %
Store at RT

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.

Certificate of Analysis / Safety Data Sheet

Certificate of Analysis: View current batch
Safety Data Sheet: View Safety Data Sheet

Furr and Tucker (1996) The preclinical development of bicalutamide: pharmacodynamics and mechanism of action. Urology 47 13. PMID: 8560673.

Tucker et al (1988) Nonsteroidal antiandrogens. Synthesis and structure-activity relationships of 3-substituted derivatives of 2-hydroxypropionanilides. J.Med.Chem. 31 954. PMID: 3361581.

Furr et al (1987) ICI 176,334: a novel non-steroidal, peripherally selective antiandrogen. J.Endocrinol. 113 R7. PMID: 3625091.

If you know of a relevant reference for this product please let us know.

Citations are publications that use Tocris products. Selected citations for Bicalutamide include:

Gambara et al (2015) TLR3 engagement induces IRF-3-dependent apoptosis in androgen-sensitive prostate cancer cells and inhibits tumour growth in vivo. J Cell Mol Med 19 327. PMID: 25444175.

Ivachtchenko et al (2014) Preclinical Development of ONC1-13B, Novel Antiandrogen for Prostate Cancer Treatment. PLoS One 5 133. PMID: 24494031.

Ishizaki et al (2013) Androgen deprivation promotes intratumoral synthesis of dihydrotestosterone from androgen metabolites in prostate cancer. Sci Rep 3 1528. PMID: 23524847.

Do you know of a great paper that uses Bicalutamide from Tocris? If so please let us know.

View Related Products by Product Action

Keywords: Bicalutamide, supplier, Non-steroidal, Androgen, receptor, antagonists, Dihydrotestosterone, Receptors, AstraZeneca, ICI176,334, chemotherapeutics, Tocris Bioscience, Androgen Receptor Antagonist products

Quick Order

Find multiple products by catalog number

divider line

Cancer Research Product Guide

Cancer Research Product Guide

Our Cancer Research Guide highlights over 750 products for cancer research. Request copy or view PDF today.

divider line

Nuclear Receptors Product Listing

Nuclear Receptors Product Listing

Our Nuclear Receptors Listing highlights over 150 products for nuclear receptors. Request copy or view PDF today.

divider line

New Products in this Area

EC 19

Synthetic retinoid; induces differentiation of stem cells

SI-2 hydrochloride

Steroid receptor coactivator 3 (SRC-3) inhibitor

SR 0987

T cell-specific RORγ (RORγt) agonist

WAY 252623

Potent LXR agonist

SR 9009

Rev-Erbα/β agonist

SR 9238

Potent and selective LXR inverse agonist

Sign-up for new product e-alerts
divider line

LinkedIn Updates

Follow Tocris on LinkedIn

Follow us on LinkedIn!

Visit our LinkedIn page for the latest Tocris news, events and updates.